TY - JOUR. T1 - Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1. AU - Schmitt, David A.. AU - Sasaki, Hidetaka. AU - Pollard, Richard B.. AU - Suzuki, Fujio. PY - 1992/10/1. Y1 - 1992/10/1. N2 - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice ...

TY - JOUR. T1 - Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1. AU - Schmitt, David A.. AU - Sasaki, Hidetaka. AU - Pollard, Richard B. AU - Suzuki, Fujio. PY - 1992/10/1. Y1 - 1992/10/1. N2 - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice ...

Background: The tumor necrosis factor alpha (TNFα) is a cytokine that produced principally by monocyte/macrophages and T lymphocytes, respectively. TNFα is recognized as the primary mediator of immunity in inflammation reaction. One important application of Tumor Necrosis Factor Receptor 2 (TNFR2) is for the treatment of autoimmune diseases like rheumatoid arthritis (RA). Objectives: The aim of this study is to examine the therapeutic trace of the recombinant humanTNFR2 on collagen-induced arthritis (CIA) in mice. Materials and Methods: CIA was created in 20 mice by immunization with bovine type II collagen (CII). After the mice were boosted on day 21, they were injected with the recombinant protein in test group (1 mg.kg-1) and assessed edema in paws and knee joints after two weeks. The quantities of inflammatory cytokines such as TNF-α, interleukin-1 beta (IL-β1), interleukin-6 (IL-6), and interleukin-10(IL-10) in serum were evaluated through enzyme-linked immunosorbent assay (ELISA) kit. In

TY - JOUR. T1 - Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-α. AU - Hardin, T. C.. AU - Koeller, J. M.. AU - Kuhn, J. G.. AU - Roodman, G. D.. AU - Von Hoff, D. D.. PY - 1993/1/1. Y1 - 1993/1/1. N2 - In conjunction with a Phase I investigation of the antineoplastic activity of recombinant human tumor necrosis factor-α (TNF-α), administered as a 28- day continuous infusion, selected nutritional parameters were evaluated to identify any effect that might be attributed to the TNF infusion. Seven clinically stable men with a variety of tumor types were studied. None had clinical or laboratory evidence of significant malnutrition before entry into the study. Five patients received 10 μg of recombinant human TNF-α per square meter per day and two patients received 25 μg/m2 per day. Indirect calorimetry assessment of resting energy expenditure, body weight, serum TNF concentration, and laboratory analysis of common nutritional markers ...

A neurotrophic factor that promotes the survival of various neuronal cell types and may play an important role in the injury response in the nervous system. Recombinant Human Epidermal Growth Factor produced in E.Coli is a single, non-glycosylated, polype

In the treatment of renal cell carcinoma both complete (CRs) and partial remissions (PRs) have been obtained using recombinant (r) interferon alpha (IFN-alpha), with response rates ranging from 0 to 31% (mean 16%). rIFN-gamma is a potent immunostimulating agent, but the clinical experience of its use is limited and results are conflicting. In a phase II study with the combination of rIFN-alpha(2c) (Boehringer Ingelheim) and rIFN-gamma (Genentech, supplied by Boehringer Ingelheim) in 31 eligible patients, a response rate of 25% was recorded. Based on this observation a randomised phase III study was initiated to investigate the possible advantage of the addition rIFN-gamma to rIFN-alpha(2c) treatment. Treatment consisted of rIFN-alpha(2c) 30 pg m(-2) = 10 x 10(6) IU m(-2) s.c. twice weekly in arm A and the same dose of rIFN-alpha combined with rIFN-gamma 100 mu g m(-2) = 2 x 10(6) IU m(-2) in arm B. Eligibility criteria included documented progression of disease; patients with bone lesions only ...

A number of recombinant plasmids coding for fusion proteins between human interferon-gamma (IFN-gamma) and human tumour necrosis factor alpha (TNF alpha) or beta (TNF beta) were constructed by using site-directed mutagenesis and ligation of the respective genes. In these proteins the whole IFN-gamma sequence of the molecule is linked at the N terminus via a short polypeptide linker to the TNF alpha sequence lacking two N-terminal amino acid residues or to the whole TNF beta sequence. A series of mutants with deletions in the interferon part of the fusion proteins were also produced. All the fusion genes obtained were efficiently expressed in Escherichia coli under the control of early promoters of bacteriophage T7. The recombinant fusion proteins were found to be unstable inside bacterial cells. Bacterial cell lysates expressing these fusion genes or their deletion mutants showed both biological activities in vitro: the antiviral activity of IFN-gamma and the cytotoxic activity of TNF.

Shop a large selection of Proteins A-Z products and learn more about MCAM (CD146) Recombinant Human Protein, hIgG1-Fc Tag, Invitrogen™ Sino Biological™ 5 x 50ug

Thermo Scientific™ Sino Biological™ FOLR1 Recombinant Human Protein, His Tag 5ug Thermo Scientific™ Sino Biological™ FOLR1...

The anti-tumor activity of recombinant human tumor necrosis factor (rHTNF) was examined against four newly induced murine sarcomas (MCA-101, -102, -105, and -106) and a murine adenocarcinoma (MCA-38) transplanted s.c. into C57BL/6 mice. The serum half-life after a single i.v. injection of rHTNF was determined to be 30 +/- 2 min. Tumor-bearing mice were more susceptible to the toxic side effects of rHTNF than were normal mice. Forty-eight percent (41/86) of tumor bearing animals that received 10 micrograms rHTNF died within 48 hr after treatment compared with no deaths in 28 normal animals receiving this dose. Treatment of mice bearing either the MCA-101, -102, -105, or -106 sarcoma or the MCA-38 adenocarcinoma with rHTNF resulted in a marked necrosis of the central portion of each tumor within 24 hr. Animals bearing the weakly immunogenic tumors MCA-105, -106, and -38 experienced a reduction in average tumor area of 47% +/- 5, 46% +/- 6, and 37% +/- 11, respectively, by 3 to 4 days after ...

Project Title: Extended cell-free protein expression system for amino acid labeling and structural biology studies at Miami Universitys Center for Bioinformatics and Functional Genomics (CBFG).. Project Lead: Carole Dabney-Smith. Email: [email protected]. Phone: (513) 529-8091. Affiliation: CAS. Other Team Members: Andor Kiss, Gary A. Lorigan. Project Details: This project is a request for a temperature regulated, heating and cooling capable, mixing, dry incubator with accessories capable of handling tube with different volumes and a starter expression kit. This will enable undergraduate and graduate student users to produce microgram to milligram quantities of in vitro expressed protein in a semi-high throughput fashion to aid in the investigation of protein structure/function relationships of any protein. One consistent barrier that impedes the progress of, discovery of structure/function relationships has been the ability to reliably and quickly generate protein, e.g., with single amino ...

TY - JOUR. T1 - Recombinant human thrombopoietin in combination with granulocyte colony- stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. AU - Somlo, George. AU - Sniecinski, Irena. AU - Ter Veer, Anna. AU - Longmate, Jeffrey. AU - Knutson, Gaylord. AU - Vuk-Pavlovic, Stanimir. AU - Bhatia, Ravi. AU - Chow, Warren. AU - Leong, Lucille. AU - Morgan, Robert. AU - Margolin, Kim. AU - Raschko, James. AU - Shibata, Stephen. AU - Tetef, Merry. AU - Yen, Yun. AU - Forman, Stephen. AU - Jones, Dennie. AU - Ashby, Mark. AU - Fyfe, Gwen. AU - Hellmann, Susan. AU - Doroshow, James H.. PY - 1999/5/1. Y1 - 1999/5/1. N2 - Lineage-specific growth factors mobilize peripheral blood progenitor cells (PBPC) and accelerate hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) may further increase the progenitor-cell content ...

This study has examined the effect of the cytokine interleukin 1 (IL-1) on metastasis formation by the human melanoma A375M in nude mice. We have found that human recombinant IL-1β (a single injection ,0.01 µg per mouse i.v. given before tumor cells) induced an augmentation of experimental lung metastases from the A375M tumor cells in nude mice. This effect was rapidly induced and reversible within 24 h after IL-1 injection. A similar effect was induced by human recombinant IL-1α and human recombinant tumor necrosis factor, but not by human recombinant interleukin 6. 5-[125I]Iodo-2′-deoxyuridine-radiolabeled A375M tumor cells injected i.v. remained at a higher level in the lungs of nude mice receiving IL-1 than in control mice. In addition, IL-1 injected 1 h, but not 24 h, after tumor cells enhanced lung colonization as well, thus suggesting an effect of IL-1 on the vascular transit of tumor cells. These findings may explain the observation of enhanced secondary localization of tumor cells ...

The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the ...

The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count , or = 1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P , 0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76). Conclusions: ...

Animal Model. Neonatal Wistar rats were randomly divided into three groups: 1) no-stroke control, 2) saline control, and 3) rhEPO treatment. The surgical procedure of whisker-barrel cortex ischemia in neonatal rats followed similar methods as described previously (Wei et al., 2006). In brief, postnatal day 7 (P7) pups were anesthetized by hypothermia. Hypothermia anesthesia was chosen because many of the drugs used to anesthetize adult animals provided inadequate anesthesia for neonates or were associated with problems such as excessively high mortality (Danneman and Mandrell, 1997). In this regard, hypothermia (immersion in ice) has been judged as a humane, safe, and effective anesthesia method for survival surgeries of neonatal rats (Danneman and Mandrell, 1997). The hypothermia procedure was kept the same for all pups in different experimental groups. Pups were placed in a noninvasive head-holder to allow for a 2.5- to 3.0-mm-diameter craniectomy through the right parietal skull. The ...

Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogrens syndrome, ...

Unconjugated Whole IgG Rabbit anti-CD3E Recombinant Monoclonal Antibody [BL-298-5D12] suitable for WB, IP, IHC, ICC, IHC-IF, F, mIF applications. Visit Bethyl.com for all your antibody needs.

What is the difference between Parental Type and Recombinant Type Chromosomes? Crossover not occurs in parental type chromosomes; in recombinant type

克拉玛尔专业提供Recombinant Human Interleukin-5高品质试剂,可查询Recombinant Human Interleukin-5价格,提供Recombinant Human Interleukin-5技术资料,Recombinant Human Interleukin-5定制合成和大包装,是专业生产各种高端试剂的制造商和供应商.联系电话4001650900

Active Recombinant human G-CSF protein is a HEK 293 Protein fragment 31 to 204 aa range, | 95% purity, | 1.000 Eu/µg endotoxin level and validated in FuncS, SDS-PAGE. The bio-activity was determined …

Buy our Recombinant Human G-CSF protein. Ab54137 is a protein fragment produced in Escherichia coli and has been validated in SDS-PAGE. Abcam provides free…

Recombinant protein production in mammalian cells is an important topic in biotechnology [1]. One of the critical steps in the production of recombinant proteins is the isolation of stable single cell clones expressing high levels of the protein of interest. Commonly, this is achieved by random genomic integration of a vector containing a promoter, a gene of interest and a selectable marker. Although this method is simple and straight forward, it lacks of reproducibility. Expression from such vectors is substantially influenced by the surrounding chromatin to the integration site and tends to be silenced over time. This makes the selection of suitable clones a tedious and time consuming procedure [1]. Several strategies have been developed to overcome the positional effects of the adjacent chromatin. For example, anti-repressor elements flanking the vectors [2] have been used or vectors have been integrated specifically into chromosomal loci with open chromatin [3]. Ideally, a vector for ...

etc. the cell physiology is affected. Cells are stressed, and this may severely affect growth, by-product accumulation, biomass yield and recombinant product yield. The stress caused by exposure to divergent microenvironments, genetic differences of individual cells, differing cell cycle stage and cell age, all contribute to make a population in a fermenter heterogeneous, resulting in cell-to-cell variation in physiological parameters of the microbial culture. Our study aims at investigating how population heterogeneity and recombinant protein production is affected by environmental gradients in bioreactors. For this purpose, a Saccharomyces cerevisiae strain, that functions as a protein production reporter, has been developed. A heterologous protein has been tagged with a fluorescent protein providing a way to measure the amount of heterologous protein produced by the cells on single cell level. Gradients are simulated in small bioreactors and the population heterogeneity can be visualised by ...

We have used transgenic mouse technology to establish immortalized hepatoma cell lines stably secreting heterologous proteins, such as human α1-antitrypsin and human factor IX. Hepatocyte-specific...

Protein titers, a key bioprocessing metric, depend both on the synthesis of protein and the degradation of protein. Secreted recombinant protein production in Saccharomyces cerevisiae is an attractive platform as minimal media can be used for cultivation, thus reducing fermentation costs and simplifying downstream purification, compared to other systems that require complex media. As such, engineering S. cerevisiae to improve titers has been then the subject of significant attention, but the majority of previous efforts have been focused on improving protein synthesis. Here, we characterize the protein uptake and degradation pathways of S. cerevisiae to better understand its impact on protein secretion titers. We do find that S. cerevisiae can consume significant (in the range of 1 g/L/day) quantities of whole proteins. Characterizing the physiological state and combining metabolomics and transcriptomics, we identify metabolic and regulatory markers that are consistent with uptake of whole ...

The following is a list of notable proteins that are generated from recombinant DNA, using biomolecular engineering, focusing on those that are used in human and veterinary medicine. In many cases, recombinant human proteins have replaced the original animal-derived version used in medicine. The prefix rh for recombinant human appears less and less in the literature. A much larger number of recombinant proteins is used in the research laboratory. These include both commercially available proteins (for example most of the enzymes used in the molecular biology laboratory), and those that are generated in the course specific research projects. Human growth hormone (rHGH): Humatrope from Lilly and Serostim from Serono replaced cadaver harvested human growth hormone human insulin (BHI): Humulin from Lilly and Novolin[disambiguation needed] from Novo Nordisk among others largely replaced bovine and porcine insulin for human therapy. Some prefer to continue using the animal-sourced preparations, as ...

Portland, Maine (PRWEB) June 18, 2014 -- Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification

Every kind of biological life process, from small to large, multiply, life and death, metabolism, is related to enzymes. If there is no catalysis of enzymes, the most basic food digestion in life and oxygen breathing can not be carried out. In fact, the various reactions occurring in the body are almost always carried out by the enzyme. It can be said that there is no enzyme, there is no life.. Here are three enzyme catalytic systems, which let us better understand the function and function of the enzyme from Creative Enzymes.. E. coli Enzyme Expression System. To date, a variety of prokaryotic and eukaryotic expression systems have been developed to produce recombinant proteins. Compared with other systems, Escherichia coli expression system has the advantages of clear genetic background, easy operation, large-scale fermentation culture, and is the most commonly used expression system at this stage. However, in the process of exogenous gene expression, there may be problems such as low ...

We have investigated the ability of recombinant TNF (mouse and human) to produce acute inflammatory lesions in an established experimental model of inflammation

Both exposure to oxygen and recombinant protein production are known to have adverse effects on microbial fermentation, including increased proteolytic and oxidative damage to the product. In an effort to characterize the effects of these stresses on the cell, DNA microarrays were used to monitor global gene expression of E. coli producing recombinant human αl-antitrypsin (α₁AT) during exposure to defined aeration conditions. Recombinant α₁AT has been shown to undergo oxygen-dependent degradation during production in E. coli, due in part to activation of the heat-shock response. The goal of this work is to better understand the effects of oxygen in order to improve this recombinant protein production process. In order to study the effects of oxygen extremes, global expression analysis was performed on α₁AT-producing cultures exposed to pure nitrogen, air, and pure oxygen. The most notable effects of oxygen exposure were those of superoxide. This reactive oxygen species is generated ...

Background Although most of antimicrobial peptides (AMPs), being relatively short, are produced by chemical synthesis, several AMPs have been produced using recombinant technology. However, AMPs could be cytotoxic to the producer cell, and if small they can be easily degraded. The objective of this study was to produce a multidomain antimicrobial protein based on recombinant protein nanoclusters to increase the yield, stability and effectivity. Results A single antimicrobial polypeptide JAMF1 that combines three functional domains based on human α-defensin-5, human XII-A secreted phospholipase A2 (sPLA2), and a gelsolin-based bacterial-binding domain along with two aggregation-seeding domains based on leucine zippers was successfully produced with no toxic effects for the producer cell and mainly in a nanocluster structure. Both, the nanocluster and solubilized format of the protein showed a clear antimicrobial effect against a broad spectrum of Gram-negative and Gram-positive bacteria, ...

Recombinant rabbit monoclonal antibody raised against EGFR. Original antibody is raised against recombinant protein corresponding to extracellular domain of mouse EGFR. (RAB00103) - Products - Abnova

Recombinant rabbit monoclonal antibody raised against full length human HSP90B1. Recombinant protein corresponding to full-length human HSP90B1. (RAB00648) - Products - Abnova

ABSTRACT: BACKGROUND: Recombinant protein production is a process of great industrial interest, with products that range from pharmaceuticals to bi...

Membrane proteins are some of the most interesting cellular proteins, serving as sensors and transducers of diverse signals, yet they also are the most…

Making Recombinant Proteins - posted in Protein Expression and Purification: My boss wants me to make a recombinant protein and this is something that I have never done before. The protein that I want to make is Recombinant Human Bone Morphogenetic Protein-7 and the product sheet of this compound where we first purchased the protein states that it is a 28.8 kDa homodimer, each subunit contains 116 amino acid residues (corresponding to amino acid residues 316 to 431 of the full-length...

The use of genetic and protein engineering techniques have led to a significant progress in animal production and it is starting to have a commercial impact in this field. Nowadays it is possible to design tailor-made sequences of enzymes, which in some cases combine specific properties of different enzymes in one molecule to obtain an optimal functional protein [181]. On the other hand, this technology allows the production of recombinant hormones through cost-effective processes using microbial cells as production hosts. In addition to this, novel strategies such as those based on passive immunization are gaining ground due to the broad range of possibilities that recombinant protein production offers. In this context, although important efforts have been done toward the minimization of recombinant protein production costs, currently, much remains still to be achieved. Cost effectiveness is particularly important in the context of animal production, where marginal returns are tight. Currently, ...

The present invention relates to a method of producing a target protein, which method comprises expressing said protein in a host cell which contains a nucleic acid molecule which encodes a chimeric

TY - JOUR. T1 - Recombinant human macrophage colony-stimulating factor in nonhuman primates. T2 - Selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells. AU - Munn, David H.. AU - Bree, Andrea G.. AU - Beall, Arthur C.. AU - Kaviani, Michelle D.. AU - Sabio, Hernan. AU - Schaub, Robert G.. AU - Alpaugh, R. Katherine. AU - Weiner, Louis M.. AU - Goldman, Samuel J.. PY - 1996/8/15. Y1 - 1996/8/15. N2 - The CD16 receptor (FcγR-III) is found on many tissue macrophages (Mφs), but its expression on circulating monocytes is restricted to a small, phenotypically distinct subset. The number of these CD16+ monocytes may be markedly increased in response to sepsis, human immunodeficiency virus infection, or metastatic malignancy. We have recently shown that the CD16+ monocyte population is selectively expanded by administration of recombinant human macrophage colony-stimulating factor (rhM-CSF). In the current study, we used the highly rhM-CSF-responsive ...

Purchase Recombinant Human Granulocyte-macrophage colony-stimulating factor(CSF2). It is produced in E.coli. High purity. Good price.

TY - JOUR. T1 - Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice. AU - Michelini, Zuleika. AU - Negri, Donatella. AU - Biava, Mirella. AU - Baroncelli, Silvia. AU - Spada, Massimo. AU - Leone, Pasqualina. AU - Bona, Roberta. AU - Blasi, Maria. AU - Nègre, Didier. AU - Klotman, Mary E.. AU - Cara, Andrea. PY - 2014/12/1. Y1 - 2014/12/1. N2 - As a prelude to immunization studies in nonhuman primates, we compared in mice the immunogenicity of a simian immunodeficiency virus (SIV)-based integrase (IN)-defective lentiviral vector (IDLV) encoding the model antigen-enhanced green fluorescence protein (eGFP) in the presence or absence of the murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) expressed from an internal ribosomal entry site (IRES) sequence. BALB/c mice were immunized once intramuscularly with IDLV expressing eGFP alone or ...

TY - JOUR. T1 - Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. AU - Dranoff, Glenn. AU - Jaffee, Elizabeth. AU - Lazenby, Audrey. AU - Golumbek, Paul. AU - Levitsky, Hyam. AU - Brose, Katja. AU - Jackson, Valerie. AU - Hamada, Hirofumi. AU - Pardoll, Drew. AU - Mulligan, Richard C.. PY - 1993/4/15. Y1 - 1993/4/15. N2 - To compare the ability of different cytokines and other molecules to enhance the immunogenicity of tumor cells, we generated 10 retroviruses encoding potential immunomodulators and studied the vaccination properties of murine tumor cells transduced by the viruses. Using a B16 melanoma model, in which irradiated tumor cells alone do not stimulate significant anti-tumor immunity, we found that irradiated tumor cells expressing murine granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulated potent, long-lasting, and specific anti-tumor ...

This randomized clinical trial examines the effect of recombinant human granulocyte colony-stimulating factor on peripheral blood leukocyte and lymphocyte cell

Abstract. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) enhanced superoxide release and membrane depolarization in parallel in human granulo

Gentaur molecular products has all kinds of products like :search , Ray Biotech \ Recombinant Human Protein kinase Casein Kinase 2 alpha, His-tagged \ 228-10284-2 for more molecular products just contact us

BACKGROUND AND AIMS: Neonatal necrotizing enterocolitis (NEC) is a common and serious acquired gastrointestinal tract condition. This clinical study assessed the potential clinical efficacy and microscopic effects of recombinant human epidermal growth factor 1-48 (EGF(1-48)) in neonates with NEC. METHODS: This prospective, double-blind, randomized controlled study included 8 neonates with NEC. The study compared the effects of a 6-day continuous intravenous infusion of EGF(1-48) at 100 ng kg(-1) h(-1) against placebo. Clinical outcomes and morphological evaluation of serial rectal mucosal biopsies were assessed at baseline and 4, 7, and 14 days after starting EGF infusions. RESULTS: There was no difference between the clinical safety outcomes recorded for EGF(1-48) or placebo patients. Quantitative morphologic differences in the rectal mucosa biopsies were noted with EGF(1-48) treatment compared with baseline or placebo and included a statistically significant increase in the number of mitoses per

Looking for recombinant human erythropoietin? Here you can find the lowest price products about recombinant human erythropoietin. We Provide for you about recombinant human erythropoietin page30

Includes bibliographical references and index. DisMeta : a meta server for construct design and optimization / Yuanpeng Janet Huang, Thomas B. Acton, and Gaetano T. Montelione -- Stable expression clones and auto-induction for protein production in E. coli / F. William Studier -- High-throughput expression screening and purification of recombinant proteins in E. coli / Natalie J. Saez and Renaud Vincentelli -- Medium-throughput production of recombinant human proteins : ligation-independent cloning / Claire Strain-Damerell [and others] -- Medium-throughput production of recombinant human proteins : protein production in E. coli / Nicola A. Burgess-Brown [and others] -- Medium-throughput production of recombinant human proteins : protein production in insect cells / Pravin Mahajan [and others] -- OmniBac : universal multigene transfer plasmids for baculovirus expression vectors systems / Deepak B. Thimiri Govinda Raj, Lakshmi S. Vijayachandran, and Imre Berger -- Multiprotein complex production ...

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases

Results. The treatment and placebo groups were of similar gestational age (29 ± 3 vs 31 ± 3 weeks) and birth weight (1376 ± 491 vs 1404 ± 508 g), and had similar Apgar scores and 24-hour Score for Neonatal Acute Physiology scores. The mortality rate was not different between treatment and placebo groups. However, the occurrence of a subsequent nosocomial infection was lower in the rG-CSF recipients (relative risk: .19; 95% confidence interval: .05-.78). rG-CSF treatment did not alter the serum concentrations of the cytokines measured (except for G-CSF). Serum G-CSF levels and blood neutrophil counts were higher in the treatment than in the placebo group 24 hours and 48 hours after dosing. ...

Human skin fibroblasts were exposed to various concentrations (from 0.01 to 5.0 units/ml) of human recombinant interleukin-1 alpha and interleukin-1 beta (IL-1 alpha and IL-1 beta). Both IL-1 alpha and IL-1 beta were found to increase dermatan-sulphate-proteoglycan (DSPG) core-protein mRNA levels. Maximal increase (3.0-fold) was seen at 48 h after addition of 1 unit of IL-1 beta/ml. In spite of the elevated DSPG-core-protein mRNA only a slight increase (from 10 to 18%) could be seen in the production of DSPG to cell-culture medium. No changes in the molecular mass of DSPG could be detected. ...

Optimising yeast as a host for recombinant protein production (review) / Nicklas Bonander and Roslyn M. Bill -- Which yeast species shall I choose? : Saccharomyces cerevisiae versus Pichia pastoris (review) / Richard A.J. Darby [and others] -- Preparation of Pichia pastoris expression plasmids / Christel Logez [and others] -- Preparation of Saccharomyces cerevisiae expression plasmids / David Drew and Hyun Kim -- Codon optimisation for heterologous gene expression in yeast / Kristina Hedfalk -- Yeast transformation to generate high-yielding clones / Mohammed Jamshad and Richard A.J. Darby -- Screening for high-yielding Pichia pastoris clones : the production of G protein-coupled receptors as a case study / Shweta Singh [and others] -- Screening for high-yielding Saccharomyces cerevisiae clones: using a green fluorescent protein fusion strategy in the production of membrane proteins / David Drew and Hyun Kim -- The effect of antifoam addition on protein production yields / Sarah J. Routledge and ...

Human Recombinant Monoclonal Antibody That Specifically Binds to VCAM-1 and Inhibits Adhesion and Transmigration Between Leukocytes and Endothelial Cells - diagram, schematic, and image 06 ...

PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.

Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs ...

The expression system was used to create recombinant human erythropoietin, a protein synthesized by the adult kidney and responsible for the regulation of red blood cell production. of recombinant EPO and increase the activity of TG-101348 this protein Yeasts have long been a model organism for biochemical and genetic studies because of the advantages they offer compared to bacterial systems, including the ease with which they can cultured and managed, and the fact that they share several important biological characteristics with eukaryotic cells, such as splicing and other processes involved in post-translational modifications. Several yeast species have been used to generate recombinant proteins, including and (examined in B?er offers similar advantages to other yeasts, and are preferred as the overall length of the mannose outer chains is shorter than in (Kang and construction of the gene The entire human erythropoietin gene was constructed using the Splicing by Overlap-Extension by PCR ...

Recombinant human erythropoietin (EPO), given intravenously, or even better, subcutaneously, represents a major advance in treating patients with end-stage renal failure. It has been studied most frequently in patients on hemodialysis and has been shown to increase hemoglobin levels, improve quality of life, and permit avoidance of transfusion with its concomitant risk of infection, iron overload, and sensitization (1). The major side effects of the medication have been hypertension and flu-like symptoms. Subcutaneous EPO can be self-administered and may require a lower dose than intravenous EPO (unfortunately, the mean maintenance dose of erythropoietin in this study was not indicated). The authors found no difference in hypertension between the 2 groups, and no unexpected side effects were reported. There has been concern that the increase in hematocrit in predialysis patients treated with EPO may be associated with acceleration of renal failure. Other studies have found no change in the ...

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is produced by our Yeast expression system and the target gene encoding Ala18-Glu144 is expressed.

We have investigated the ability of recombinant TNF (mouse and human) to produce acute inflammatory lesions in an established experimental model of inflammation. Upon intradermal injection in rabbit skin, TNF, in amounts as low as 3 x 10(-14) mol/site, was found to be very potent at inducing local neutrophil accumulation and neutrophil-dependent oedema formation, thereby fulfilling two important criteria to be considered as an inflammatory mediator. Our findings further indicate that the pro-inflammatory properties of TNF are probably more related to its immediate stimulatory effects on neutrophils rather than to its slow (protein biosynthesis-dependent effects on endothelial cells. Our data thus show that very low amounts of mouse and human recombinant TNF can initiate an acute inflammatory reaction in vivo in rabbit skin and that TNF is able to evoke two of the four cardinal signs of inflammation. ...

Introduction. The use of recombinant DNA technology can only benefit humans Recombinant DNA technology is the combining of the DNA from one organism with DNA from another organism. There are many steps in creating recombinant DNA. It begins with the isolation of a gene of interest. This gene is cut using restriction enzyme which will cut the gene in a particular place. A vector is taken and cut open with the same restriction enzyme as the gene was cut with. A vector is a piece of DNA that is capable of growth. Common vectors are of that of a bacterial plasmid. Once vector and gene have been cut they are joined at their sticky ends by using DNA ligase. The viruses and transgenic bacteria used as vectors in the recombinant DNA technology could undergo mutilation which could produce a new pathogen which we wont be able to control. Recombinant DNA technology can have many benefits to humans; one of these benefits is the process of gene therapy. Gene therapy is a way of treating disease by either ...

Recombinant DNA Technology Market research Report is a valuable supply of perceptive information for business strategists. This Recombinant DNA Technology Market study provides comprehensive data which enlarge the understanding, scope and application of this report.. A specific study of competitive landscape of the global Recombinant DNA Technology Market has alloted, providing insights into the corporate profiles, financial standing, recent developments, mergers and acquisitions, and therefore the SWOT analysis. This analysis report will provides a transparent plan to readers concern regarding the general market situation to further choose on this market projects.. Get Sample Copy of this Report @ https://www.reportsintellect.com/sample-request/922068 The Recombinant DNA Technology Market report profiles the following companies, which includes: - Monsanto Company , Roche , Biogen , Amgen , Novartis , Eli Lilly and Company , GenScript , Pfizer Inc. , Novo Nordisk , Sanofi , Merck KGaA , ...

Non-glycosylated, recombinant human granulocyte colony-stimulating factor (rhG-CSF), produced by Escherichia coli(filgrastim, leukostim) is widely used to treat a number of serious human diseases...

Pichia pastoris recombinant protein expression platform. Automated purification by affinity chromatography on Ni-NTA and enzymatic activities assays of His6-tag

Background: Vacuum sealing drainage (VSD) and epidermal growth factor (EGF) both play an important role in the treatment of wounds. This study aims to explore the effect of the combination of VSD and EGF on wound healing and the optimal concentration and time of EGF.|st...

Search for Recombinant Human Erythropoietin Alfa / Epoetin Alfa (50mcg) Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.

The present invention provides an expression system for producing recombinant human erythropoietin (rhEPO) exhibiting biological activity and immunochemical properties of the native human erythropoietin (hEPO). Also provided is an improved method for purifying rhEPO from culture medium by two-step column chromatography.

For recombinant polypeptide purification, bacteria expressing GST-tagged or His-tagged proteins were cultured until the OD600 reached 0.5, and then they were incubated with 1 mM IPTG. After optimization of GST-tagged domain-specific FVIII polypeptide expression conditions, protein fragments were purified using GST affinity chromatography.. For GST-tagged recombinant polypeptide validation, a GST pull-down assay was performed as described above. During blood clotting, coagulation factor IXa (FIXa) is known to bind FVIII via the A2 domain [1516]. Therefore, we tested whether each domain bound to recombinant FIX or platelet-derived FIX in standard human plasma. Results of the GST pull-down assay were shown by western blot analysis using the anti-FIX antibody. GST-tagged FVIII domain polypeptides were identified using the anti-GST antibody. All GST-tagged FVIII domain polypeptides were detected at the expected sizes among the pull-down products along with recombinant FIX (Fig. 3A and 3B). In ...

title: Analysis of the production efficiency and titration of various recombinant adeno-associated viruses, doi: none, category: Article

BACKGROUND: AVI-014 is an egg white-derived, recombinant, human granulocyte colony-stimulating factor (G-CSF). This healthy volunteer study is the first human investigation of AVI-014. METHODS: 24 male and female subjects received a single subcutaneous injection of AVI-014 at 4 or 8 mcg/kg. 16 control subjects received 4 or 8 mcg/kg of filgrastim (Neupogen, Amgen) in a partially blinded, parallel fashion. RESULTS: The Geometric Mean Ratio (GMR) (90% CI) of 4 mcg/kg AVI-014/filgrastim AUC(0-72 hr) was 1.00 (0.76, 1.31) and Cmax was 0.86 (0.66, 1.13). At the 8 mcg/kg dose, the AUC(0-72) GMR was 0.89 (0.69, 1.14) and Cmax was 0.76 (0.58, 0.98). A priori pharmacokinetic bioequivalence was defined as the 90% CI of the GMR bounded by 0.8-1.25. Both the white blood cell and absolute neutrophil count area under the % increase curve AUC(0-9 days) and Cmax (maximal % increase from baseline)GMR at 4 and 8 mcg/kg fell within the 0.5-2.0 a priori bound set for pharmacodynamic bioequivalence. The CD 34+ % increase

The recombinant human G-CSF (rhG-CSF) synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. Filgrastim was first marketed by Amgen with the brand name Neupogen. Several bio-generic versions are now also available in markets such as Europe and Australia. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta) are two commercially available forms of rhG-CSF. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections. Another form of rhG-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies. ...

GM-CSF Receptor alpha recombinant proteins are produced in house and quality guaranteed.All the GM-CSF Receptor alpha recombinant proteins are in stock.

Diphtheria toxin A (DTA), a segment of the diphtheria toxin (tox), inhibits protein synthesis in cells. When released from a cell, DTA is nontoxic and cannot enter other cells independently without the help of diphtheria toxin B. In this study, we artificially synthesized the DTA gene sequence and cloned it into pEGFP-N1 to generate the recombinant vector pEGFP-N1-DTA. This recombinant vector was then transfected into 293T cells to observe the effect of DTA protein expression on enhanced green fluorescent protein (EGFP) protein expression and the proliferation of 293T cells. After 48 h, high levels of EGFP expression were seen in control pEGFP-N1-transfected cells, whereas very low levels were seen in cells transfected with pEGFP-N1-DTA. Reverse transcription polymerase chain reaction confirmed the expression of the DTA gene in cells transfected with pEGFP-N1-DTA. Further, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay revealed a significant difference in cell proliferation

A major obstacle in designing effective vaccines is our limited knowledge of the mechanisms involved in eliciting a protective cell-mediated immune response. In recent years, research has focused on the development of recombinant vaccines, in which antigenic peptides derived from a specific pathogen are delivered to the cells via live vectors. For a vaccine to be effective in an out-bred population it must generate as many antigenic determinants as possible. One method that can be used to generate multiple peptide determinants is to express two or more recombinant proteins from a single live vaccine vector. To this end, we developed a recombinant vaccinia virus system that expresses two full-length influenza virus proteins; nucleoprotein (NP) and acidic polymerase (PA). In addition to the NP and PA proteins, our expression system is designed to produce yellow and red fluorescent proteins, which allow us to monitor, in a quantitative manner, recombinant protein expression both in vitro and in ...

CSPC Pharma is developing pegfilgrastim (PEG-rhG-CSF), a pegylated recombinant granulocyte colony-stimulating factor receptor agonist, for the prevention of

Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising al DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cells, whereby the soluble proteins are secreted into the medium.

Materials. U0126 and PD98059, two specific inhibitors of the ERK1/2 MAPK pathway, and SB202190, a specific inhibitor of the p38 MAPK pathway, were purchased from Calbiochem (VWR International, Fontenay-sous-bois, France). U0126, PD98059, and SB202190 were dissolved in dimethyl sulfoxide and used at final concentration of 10 μM, as described previously (Muselet-Charlier et al., 2007). SP600125, a selective inhibitor of JNK catalytic activity (Bennett et al., 2001), and recombinant human tumor necrosis factor α (TNF-α) were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France) and used at a final concentration of 3 μM and 10 ng/ml, respectively. Eagles minimum essential medium with Earles salts, penicillin-streptomycin, and l-glutamine were purchased from Invitrogen SARL (Cergy Pontoise, France). Fetal bovine serum was purchased from Eurobio (Courtaboeuf, France).. Cell Culture. The human CF bronchial epithelial cell lines IB3-1 and CFBE41o- were used. IB3-1 was a bronchial ...

Tumor necrosis factor alpha (TNF-alpha) is a cytokine that belongs to the tumor necrosis factor (TNF) superfamily. TNF-alpha is mainly secreted by macrophages. TNF-alpha is involved in the regulat...

Although there are many different expression systems for recombinant production of pharmaceutical proteins, many of these suffer from drawbacks such as yield, cost, complexity of purification, and possible contamination with human pathogens. Microalgae have enormous potential for diverse biotechnological applications and currently attract much attention in the biofuel sector. Still underestimated, though, is the idea of using microalgae as solar-fueled expression system for the production of recombinant proteins. In this study, we show for the first time that completely assembled and functional human IgG antibodies can not only be expressed to high levels in algal systems, but also secreted very efficiently into the culture medium. We engineered the diatom Phaeodactylum tricornutum to synthesize and secrete a human IgG antibody against the Hepatitis B Virus surface protein. As the diatom P. tricornutum is not known to naturally secrete many endogenous proteins, the secreted antibodies are already very

Natural Spray for skin repair after laser E-light treatment, derma treatment, microneedle dermaroller treatment and minor skin wound injuries. Prevents post-operative bruising, swelling, and infection. WHATS INSIDE 1x Freeze-dried powder1x 2ml; 1 solution: 6m1x 0.1ml quantitative nozzle STORAGE: Keep product in a seal

1FGA: Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution.

High quality EPO/Recombinant Human Erythropoietin Injection(CHO Cell) Contact info: e-mail:[email protected] skype:live:sunnylidi whatsapp:+8613735524230 http://www.holyuniverse-pharm.com Introduction Modified GRF 1-29(Cjc1295) and...